Open an account

Entera Bio

ENTX · NASDAQ

$3.02+$0.08 (+2.72%)TodayMarket closed ·
Prev close $2.94

About ENTX

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Employees
20
Headquarters
Jerusalem
Listed
Jun 28, 2018
Sector
Health Care
Industry
Biotechnology
Website
enterabio.com

ENTX key statistics

Market cap
525.25M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
678.90K
Volume
791.93K
Open price
$2.94
High today
$3.26
Low today
$2.79
52 Week high
$4.20
52 Week low
$0.91

Entera Bio (ENTX) at a glance

Entera Bio (ENTX) last traded at $3.02, with a market cap of 525.25M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.79 and $3.26. The current price is 8.2% above the day's low and 7.4% below its high.

Volume so far is 791.93K shares, in line with the average of 678.90K shares a day.

Over the past year Entera Bio has ranged from $0.91 to $4.20, and now sits 64% of the way up that range.

Entera Bio met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.0816.

The average analyst price target is $9.86, 226.5% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $9.86
Low
$9.09
Now
$3.02
High
$11.55

ENTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 31.8% on average.

  1. Q3 FY24: reported -$0.08 per share against an estimate of -$0.051
  2. Q4 FY24: reported -$0.06 per share against an estimate of -$0.0816
  3. Q1 FY25: reported -$0.06 per share against an estimate of -$0.0714
  4. Q2 FY25: reported -$0.06 per share against an estimate of -$0.1122
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0918
  6. Q4 FY25: reported -$0.07 per share against an estimate of -$0.0918
  7. Q1 FY26: reported -$0.07 per share against an estimate of -$0.153
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.0816

ENTX news

  • Avi Kapoor

    Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

  • Press releasePRNewswire

    Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

  • Akanksha Bakshi

    Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk

  • Avi Kapoor

    Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June

  • Avi Kapoor

    Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings

  • Entera Bio Announces FDA Has Provided Positive Feedback On The Phase 3 Protocol For EB613, The Company's Oral Osteoporosis Tablet

  • Press releaseGlobe Newswire

    Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market

  • Press releaseGlobe Newswire

    BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Similar companies

Companies in the same industry as Entera Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.